Status: Recruiting
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 20, 2026Locations: 1
Eligibility criteria
Patients ≥18 years with histology-proven R/M salivary gland cancer. [+15]
Prior radiation therapy (or other non-systemic therapy) within 2 weeks prior to... [+17]